[Evaluation of 31 cases treated with bevacizumab-based chemotherapy].
The combination of bevacizumab and standard chemotherapy prolongs progression-free survival and improves response rates in advanced nonsquamous non-small-cell lung cancer(NSCLC). We evaluated the efficacy and safety of bevacizumab based chemotherapy in 31 cases of NSCLC. Adverse events occurred in all patients. Grade≥3 hematotoxicities were seen in 27 patients(87. 0%). Grade≥3 non-hematotoxicities were seen in 13 patients(41. 9%). Bevacizumab-related adverse events included epistaxis(74. 2%), hypertension(22. 6%), and proteinuria(22. 6%). Hemoptysis was reported in 9 patients( 29. 0%), but there was no pulmonary hemorrhage or severe hemoptysis. The treatment results of the 18 patients were evaluated as followes: partial response(PR)10, stable disease(SD)7, and progressive disease(PD)1 patient. The response rate(CR+PR)and disease control rate(CR+PR+SD)were 55. 6%and 94. 4%, respectively. The response rates were 66. 7%, 50. 0%, and 57. 1% for 1st-line(6 patients), 2nd-line and later(12 patients), and postoperative recurrence(7 patients all after 2nd-line)patients, respectively. Bevacizumab-based chemotherapy is an efficacious and safe treatment for advanced nonsquamous NSCLC.